Isolated limb perfusion with tumor necrosis factor‐α and melphalan for patients with unresectable soft tissue sarcoma of the extremities

Since 1992, isolated limb perfusion (ILP) with tumor necrosis factor‐α (TNFα) and melphalan has been used for the treatment of patients with unresectable soft tissue sarcomas of the extremities. The authors retrospectively studied the results of limb salvage surgery using TNFα‐ILP at their institution.

[1]  Safdar N. Khan,et al.  Rehabilitation for limb salvage patients , 2001, Cancer.

[2]  A. Eggermont,et al.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectives , 2001, Current oncology reports.

[3]  R. Mirimanoff,et al.  Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[5]  B. Vrouenraets,et al.  Toxicity and morbidity of isolated limb perfusion. , 1998, Seminars in surgical oncology.

[6]  W. Molenaar,et al.  Feasibility and Efficacy of External Beam Radiotherapy after Hyperthermic Isolated Limb Perfusion with TNF-α and Melphalan for Limb-saving Treatment in Locally Advanced Extremity Soft-tissue Sarcoma , 1998 .

[7]  W. Molenaar,et al.  Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. , 1998, International journal of radiation oncology, biology, physics.

[8]  M. Inbar,et al.  High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation , 1997, Cancer.

[9]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[10]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Vrouenraets,et al.  Thirty‐five years of isolated limb perfusion for melanoma: Indications and results , 1996, The British journal of surgery.

[12]  A. Willemsen,et al.  FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  D H Leung,et al.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Lejeune,et al.  High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. , 1995, European journal of cancer.

[15]  A. Eggermont,et al.  Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. , 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  A. Taïeb,et al.  Ex vivo reconstruction of a pigmented epidermis , 1994 .

[17]  M. Simon,et al.  Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. , 1994, The Journal of bone and joint surgery. American volume.

[18]  A. Eggermont,et al.  Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. , 1994, Melanoma research.

[19]  N. Santoro,et al.  Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. , 1994, Melanoma research.

[20]  E. Casper,et al.  Comparison of Amputation With Limb‐sparing Operations for Adult Soft Tissue Sarcoma of the Extremity , 1992, Annals of surgery.

[21]  B. Kroon,et al.  Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities , 1989, Cancer.

[22]  D. Rosenthal,et al.  Treatment of the patient with stage M0 soft tissue sarcoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Kroon,et al.  Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  J. Coindre,et al.  Reproducibility of a histopathologic grading system for adult soft tissue sarcoma , 1986, Cancer.

[25]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[26]  J. Tepper,et al.  The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. , 1982, Annals of surgery.

[27]  H. Wanebo,et al.  Soft tissue sarcoma. , 1997, Medicine and health, Rhode Island.

[28]  C. Wiltschke,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Eggermont,et al.  Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. , 1995, Archives of surgery.

[30]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Willett,et al.  Radiation therapy of sarcomas of the soft tissues. , 1991, Cancer treatment and research.

[32]  J. Godbold,et al.  Prognostic factors for local recurrence and survival in patients with localized extremity soft-tissue sarcoma. , 1988, Seminars in surgical oncology.

[33]  S. Rosenberg,et al.  Quality of life assessment of patients in extremity sarcoma clinical trials. , 1982, Surgery.